U.S. Logistics Stock News

NYSEAM:TMP
NYSEAM:TMPBanks

Tompkins Financial (TMP) Posted Stronger Earnings And Raised Its Dividend, Is It Still Cheap?

Tompkins Financial (TMP) has drawn fresh investor attention after reporting higher second quarter and first half 2026 earnings, along with a 4.5% increase in its regular quarterly dividend to $0.70 per share. See our latest analysis for Tompkins Financial. At a share price of $99.89, Tompkins Financial has delivered a 30 day share price return of 6.8% and a year to date share price return of 37.76%. Its 1 year total shareholder return of 67.14% and 3 year total shareholder return of 97.92%...
NYSE:PHM
NYSE:PHMConsumer Durables

PulteGroup (PHM) Expands In Northwest Florida, Is The Stock 32% Undervalued?

PulteGroup (PHM) has expanded into Northwest Florida with a new Florida Panhandle Division, tied to a builder agreement for up to 2,653 homesites. This move gives investors fresh context for assessing the stock. See our latest analysis for PulteGroup. The recent Northwest Florida expansion sits alongside a mixed price picture, with the share price down 2.60% over the last day but up 10.21% on a 90 day share price return and supported by a 5 year total shareholder return of 149.49%. This...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics (TGTX) Is Down 7.4% After Q2 Profit Drop Despite Higher 2026 Revenue Guidance – Has The Bull Case Changed?

TG Therapeutics, Inc. reported past second-quarter 2026 results with revenue of US$240.34 million versus US$141.15 million a year earlier, while net income declined to US$7.78 million from US$28.19 million and diluted EPS from continuing operations was US$0.05 compared with US$0.17. Despite weaker profitability, management raised full-year 2026 global revenue guidance to approximately US$950 million, underscoring confidence in the commercial trajectory of its B-cell disease franchise. We’ll...
NYSE:HASI
NYSE:HASIDiversified Financial

Is HA Sustainable Infrastructure Capital (HASI) Undervalued On Its Q2 Earnings Beat?

Why HA Sustainable Infrastructure Capital’s latest earnings matter HA Sustainable Infrastructure Capital (HASI) reported second quarter 2026 results that exceeded market expectations on both revenue and earnings per share. The company also highlighted continued demand for its climate focused infrastructure projects. See our latest analysis for HA Sustainable Infrastructure Capital. After the earnings beat and dividend affirmation on 6 August 2026, HA Sustainable Infrastructure Capital’s share...
NasdaqGS:IPAR
NasdaqGS:IPARPersonal Products

Interparfums (IPAR) Is Down 5.2% After Reaffirming 2026 Outlook Amid Margin Pressure And Dividend Declaration

Interparfums, Inc. recently reported second-quarter 2026 results showing sales of US$341.04 million and net income of US$30.49 million, while also declaring a regular quarterly cash dividend of US$0.80 per share payable on September 30, 2026, to shareholders of record on September 15, 2026. Despite modest sales growth and slightly lower earnings, management reaffirmed its full-year 2026 outlook, including expected sales of US$1.48 billion and EPS of US$4.85, and highlighted a robust 2027...
NYSE:DHI
NYSE:DHIConsumer Durables

D.R. Horton (DHI) Looks 12% Undervalued, Is More Upside Still Ahead?

D.R. Horton (DHI) has drawn investor attention after recent share price moves, with the stock down about 6% over the past month and slightly lower over the past year. This shift invites a closer look. See our latest analysis for D.R. Horton. D.R. Horton’s recent 1 day share price decline of 3.6% and 30 day share price return down 6.2% sit against a 5 year total shareholder return of 58.0%. This points to fading near term momentum but a still positive longer term record. If this shift in...
NYSE:KOP
NYSE:KOPChemicals

Koppers Holdings (KOP) Is Up 6.8% After Q2 Loss And Maintained Dividend Decision – What's Changed

Koppers Holdings Inc. reported past second-quarter 2026 results showing sales rising to US$520.1 million from US$504.8 million a year earlier, but swinging from US$16.4 million in net income to a US$147.5 million net loss, while also affirming a quarterly dividend of US$0.09 per share payable in September 2026. Despite the move to a large loss and basic loss per share of US$7.71 from prior earnings of US$0.83, the decision to maintain its dividend suggests management is balancing shareholder...
NasdaqGS:WMT
NasdaqGS:WMTConsumer Retailing

Walmart (WMT) Stock May Trade Above Fair Value After Its 140% Run

Walmart stock has delivered a strong 139.5% return over the past five years, yet current checks suggest investors are now paying a premium to the latest intrinsic value estimate from a Discounted Cash Flow (DCF) model. With analysts recently turning more cautious on near term growth, even as the company pushes into areas like connected TV advertising and drone delivery, pricing looks less straightforward than the recent run might suggest. Over five years, Walmart has returned 139.5%, which...
NasdaqGS:SVC
NasdaqGS:SVCHotel and Resort REITs

Service Properties Trust (SVC) Could Be 262% Overvalued On Q2 Losses

Why Service Properties Trust’s Latest Earnings Matter For Investors Service Properties Trust (SVC) has drawn fresh attention after reporting second quarter 2026 results, with revenue of $420.97 million and a net loss of $223.84 million compared with the prior year period. See our latest analysis for Service Properties Trust. The earnings release on 5 August has arrived after a mixed period for Service Properties Trust, with the share price up 7.23% on the day, while the year-to-date share...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

Is CrowdStrike Holdings (CRWD) Fully Valued As Fal.Con 2026 And Its AI Security Challenge Draw Interest?

Why Fal.Con 2026 and AI security experiments matter for CrowdStrike stock CrowdStrike Holdings (CRWD) has drawn fresh attention after Fal.Con 2026 sold out faster than prior years and the company launched a global AI security challenge with Amazon Web Services. Both initiatives sit at the intersection of cybersecurity and artificial intelligence, a theme many investors already link closely with CrowdStrike. They also arrive only weeks before the company’s next earnings release on August 26,...
NasdaqCM:XPEL
NasdaqCM:XPELAuto Components

Why XPEL (XPEL) Is Up 8.0% After Raising EPS And Revenue Guidance - And What's Next

In early August 2026, XPEL, Inc. reported past second-quarter results showing year-over-year increases in revenue to US$143.05 million and net income to US$18.04 million, and issued third-quarter 2026 revenue guidance of approximately US$137 million to US$139 million. The company’s higher earnings per share alongside fresh revenue guidance offers investors clearer visibility into recent performance and near-term expectations. Next, we’ll examine how XPEL’s higher earnings per share guidance...
NasdaqGS:AEP
NasdaqGS:AEPElectric Utilities

Nuclear Energy Stocks Retail Investors Are Screening For Stable Power Exposure

Energy markets keep feeling the impact of oil price gains tied to Strait of Hormuz risks, which keeps inflation worries alive and central banks cautious on rate cuts. That keeps reliable, low carbon baseload power like nuclear energy on investor radar as an alternative to fuel dependent generation. This article highlights 3 nuclear energy stocks from our screener that stand out for their business focus, exposure to the theme, and risk profile. The 3 nuclear energy stocks below are just a...
NYSE:MTDR
NYSE:MTDROil and Gas

The Bull Case For Matador Resources (MTDR) Could Change Following Strong Q2 Cash Flows And Higher 2026 Output

In the second quarter of 2026, Matador Resources Company reported revenue of US$1,186.39 million and net income of US$390.65 million, with higher oil and gas production versus a year earlier and earnings per share beating analyst expectations. The company also generated near-record adjusted free cash flow of US$303 million, used US$200 million to pay down debt, raised its full-year 2026 production guidance, and reported a 5% increase in proved reserves, extending its development runway...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Travere Therapeutics (TVTX) Gets A Fresh Valuation Test As FILSPARI Fuels Q2 Revenue

Travere Therapeutics (TVTX) drew increased attention after reporting second quarter 2026 results, with revenue of US$169.58 million and a wider net loss of US$34.8 million as FILSPARI uptake expanded. See our latest analysis for Travere Therapeutics. At a share price of US$62.45, Travere Therapeutics has seen strong momentum build, with a 90 day share price return of 46.6% and a one year total shareholder return of 269.31% that reflects changing expectations around its rare kidney...
NYSE:SE
NYSE:SEMultiline Retail

Sea (SE) Slides Before Earnings, Is It Still 21% Below Fair Value?

Sea (SE) is back in focus after its stock declined 3.4% to close at US$111.00, just days before its August 11 earnings release that will update investors on recent business trends. See our latest analysis for Sea. Following the recent 1-day share price decline of 3.4% to US$111.00, Sea still shows stronger short term momentum with a 90-day share price return of 27.98%. However, the 1-year total shareholder return is down 25.43% and the 5-year total shareholder return is down 63.75%, which...
NYSE:WRBY
NYSE:WRBYSpecialty Retail

Warby Parker (WRBY) Could Be 10% Undervalued Following Profit Return And Guidance Reaffirmation

Warby Parker (WRBY) just posted its second quarter 2026 results, reporting higher revenue, a swing to profit, and reaffirmed full year guidance. The company also highlighted progress in vision care services and the upcoming Intelligent Eyewear product line. See our latest analysis for Warby Parker. Warby Parker shares closed at US$26.96 on 6 August 2026, with the stock falling 7.89% on the day yet still showing a 19.19% year to date share price gain and a very large 3 year total shareholder...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

AI Infrastructure Stocks That Could Benefit Most From Cooling Rate Fears

With Nasdaq futures pointing higher while investors wait for fresh jobs data and inflation clues, attention is swinging back to large technology stocks that often react quickly to shifting rate expectations. This mix of cautious optimism and inflation worries creates an opening for those watching how tech giants are exposed to the latest economic headlines. This article walks through 3 stocks from our Technology Sector Stocks screener that appear positively exposed to the current news. The...
NYSE:DGX
NYSE:DGXHealthcare

The Bull Case For Quest Diagnostics (DGX) Could Change Following Raised Guidance And New Self-Collection Services

In late July 2026, Quest Diagnostics introduced self-collection services for bacterial vaginitis and other common genital tract infections across more than 2,000 patient service centers, alongside publishing large-scale study data on co-infection risks and diagnostic value of modern molecular testing. At the same time, Quest raised its full-year 2026 revenue and earnings guidance after reporting stronger second quarter sales and net income versus the prior year, underscoring how its...
NasdaqGS:XMTR
NasdaqGS:XMTRTrade Distributors

Is Xometry (XMTR) Undervalued After Earnings Growth And Higher 2026 Guidance?

Xometry (XMTR) is back in focus after its 4 August 2026 earnings report, which showed higher quarterly and year to date sales, narrower net losses and an updated outlook for the rest of 2026. See our latest analysis for Xometry. Despite a 1 day share price return of down 5.7% to US$87.09 after the 4 August earnings release, Xometry’s year to date share price return of 38.8% and 1 year total shareholder return of 102.2% suggest momentum has been building over a longer window. The 3 year total...
NasdaqGS:PODD
NasdaqGS:PODDMedical Equipment

Insulet (PODD) Is Down 15.9% After Cutting 2026 Revenue Guidance on Type 2 Retention Strains

In early August 2026, Insulet Corporation reported second-quarter 2026 results showing revenue of US$801.7 million and net income of US$95 million, with basic and diluted EPS of US$1.37, while also trimming full-year 2026 revenue growth guidance to 21%–23% amid softer U.S. Omnipod demand and type 2 retention issues. Beneath the headline beat, management highlighted weaker-than-expected utilization and retention among U.S. type 2 diabetes users and ongoing product quality and litigation...